Evidence map›Paper›PMID 37909013›Full record

ReviewFrontiers in oncology2023

The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey.

Marta Rodriguez Castells, Iosune Baraibar, Javier Ros, Nadia Saoudi, Francesc Salvà, Ariadna García, Adriana Alcaraz, Josep Tabernero, Elena Élez

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta Rodriguez CastellsMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Iosune BaraibarMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Javier RosMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Nadia SaoudiMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Francesc SalvàMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Ariadna GarcíaVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Adriana AlcarazVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Josep TaberneroMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Elena ÉlezMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The journey of metastatic colorectal cancer patients is complex and challenging, requiring coordination and collaboration between multiple healthcare providers. Understanding patients' needs, fears, feelings, concerns, and behaviors is essential for providing individualized patient-centered care. In recent years, mCRC patients have experienced improvements in clinical outcomes, from 16 months of overall survival to 32 months, thanks to research. However, there is still room for improvement, and integrating clinical and translational research into routine practice can help patients benefit from treatments and techniques that would not be an option. In the Journey of mCRC patients, living well with cancer and quality of life becomes a priority given the outcomes of the disease. Patient reported outcomes (PRO) and Patient Reported Outcome Measures (PROMs) are becoming therefore new estimands in Oncology. Patient advocates represent important figures in this process by prioritizing issues and research questions; evaluating research designs and the performance of the research; the analysis and interpretation of data; and how results are disseminated. Multidisciplinary Tumor Boards and shared decision-making is essential for designing treatment strategies for individual patients. Quality of Life is often prioritized only when it comes to refractory advanced disease and end-of-life care, but it has to be integrated from the beginning, as the emotional impact of diagnosis leads to a vulnerable situation where patients' needs and preferences can be easily overseen. First-line treatment will be chosen among more treatment options than subsequent lines, with longer progression-free survival and a bigger impact on the outcomes. Practicing patient-centered care and optimizing first-line treatment for colorectal cancer patients requires a comprehensive understanding of patient experience and treatment outcomes, which can guide clinical practice and inform regulatory decisions for the benefit of patients.

Indexed as

colorectal cancerpatient journeypatient reported outcome measurespatient reported outcomesquality of life

Identifiers

PMID37909013
PMCPMC10614292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.